Horby, Peter W. and Peto, Leon and Staplin, Natalie and Campbell, Mark and Pessoa-Amorim, Guilherme and Mafham, Marion and Emberson, Jonathan R. and Stewart, Richard and Prudon, Benjamin and Uriel, Alison and Green, Christopher A. and Dhasmana, Devesh J. and Malein, Flora and Majumdar, Jaydip and Collini, Paul and Shurmer, Jack and Yates, Bryan and Baillie, J. Kenneth and Buch, Maya H. and Day, Jeremy and Faust, Saul N. and Jaki, Thomas and Jeffery, Katie and Juszczak, Edmund and Knight, Marian and Lim, Wei Shen and Montgomery, Alan and Mumford, Andrew and Rowan, Kathryn and Thwaites, Guy and Haynes, Richard and Landray, Martin J. (2024) Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. NATURE COMMUNICATIONS, 15 (1): 924. ISSN , 2041-1723
Full text not available from this repository. (Request a copy)Abstract
Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised withCOVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | PLACEBO-CONTROLLED PHASE-3; ORAL BG-12; |
| Subjects: | 000 Computer science, information & general works > 004 Computer science 300 Social sciences > 310 General statistics |
| Divisions: | Informatics and Data Science > Department Machine Learning & Data Science > Lehrstuhl für Computational Statistics (Prof. Dr. Thomas Jaki) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 14 Aug 2025 05:27 |
| Last Modified: | 14 Aug 2025 05:27 |
| URI: | https://pred.uni-regensburg.de/id/eprint/65665 |
Actions (login required)
 |
View Item |
